Nivolumab versus Cabozantinib: Comparing Overall Survival in Metastatic Renal Cell Carcinoma.

by Witold Wiecek, Helene Karcher
Published 2016-01-01

Cabozantinib versus everolimus, nivolumab, axitinib, sorafenib and best supportive care: A network meta-analysis of progression-free survival and overall survival in second line tr...

by Billy Amzal, Shuai Fu, Jie Meng, Johanna Lister, Helene Karcher
Published 2017-01-01

The “RCT augmentation”: a novel simulation method to add patient heterogeneity into phase III trials

by Helene Karcher, Shuai Fu, Jie Meng, Mikkel Zöllner Ankarfeldt, Orestis Efthimiou, Mark Belger, Josep Maria Haro, Lucien Abenhaim, Clementine Nordon, on behalf of the GetReal Consortium Work Package 2
Published 2018-07-01